Trial results

$MIRM — brelovitug

Mirum Pharmaceuticals, Inc. (MIRM) brelovitug: trial results in hepatitis D virus (HDV) infection, 2026.

Research by Catalyst Intel

The catalyst

"Topline results from the Phase 3 AZURE-4 study, the second of the two pivotal studies supporting the U.S. registration package, are expected in the fourth quarter of 2026."

— Mirum Pharmaceuticals, Inc., 8-K filed 2026-09-28 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MIRM-BRELOVITUG-2026

Company

Mirum Pharmaceuticals, Inc.

Kind

Trial results

Indication

hepatitis D virus (HDV) infection

Window

2026-01-01 – 2026-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-01-30; subscribers get it on the day.